The DOI matches its Crossref record.
Effect of Tirzepatide on Kidney Function in People with Excess Body Weight: A Post Hoc Analysis of the SURMOUNT-1 Trial: FR-OR47
Abstract
Background: The prevalence of chronic kidney disease due to obesity is rapidly increasing, but few proven effective therapies are available. Tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has shown potential in attenuating the decline in estimated glomerular filtration rate (eGFR) in people with type 2 diabetes (T2D) at high risk for cardiovascular disease. In the SURMOUNT-1 trial in people with obesity or overweight without T2D, tirzepatide significantly reduced body weight and blood pressure by week 72 (the primary endpoint) compared with placebo. This post-hoc analysis assessed the potential impact of tirzepatide compared with placebo on kidney function in SURMOUNT-1 trial participants. Methods: Data from all participants randomly assigned to treatment were included (pooled tirzepatide [5, 10, and 15 mg], N = 1896; placebo, N = 643). Assessments included CKD-EPI creatinine- and cystatin-C-based eGFR (Cr-eGFR and CysC-eGFR, respectively), and urine albumin-to-creatinine ratio (UACR). The change from baseline to week 72 was analyzed using a mixed model for repeated measures with on-treatment data. Results: Baseline mean Cr-eGFR was 98.1±18.0 mL/min/1.73m2 and CysC-eGFR was 95.5±19.1 mL/min/1.73m2; 27%-36% of participants had mean eGFR <90 mL/min/1.73m2. Baseline median UACR was 6.0 mg/g (interquartile range 4.0-11.0 mg/g); 8.6% of participants had UACR ≥30 mg/g. The estimated treatment difference (ETD) between pooled tirzepatide groups and placebo on the change from baseline Cr-eGFR was -0.2 mL/min/1.73m2 (95% confidence interval [CI] -1.2, 0.9; p=0.780). For CysC-eGFR the ETD was 3.2 mL/min/1.73m2 (95% CI 2.1, 4.3; p<0.001). The ETD on the percent change in UACR was -8.4% (95% CI -14.7, -1.6; p=0.017). In participants with baseline UACR ≥30 mg/g, the ETD was -42.3% (95% CI -60.8, -15.0; p=0.006). Conclusions: Tirzepatide demonstrated an increase in CysC-eGFR and reductions in UACR compared with placebo, suggesting renoprotective effects. These results warrant a long-term, prospective kidney outcome trial for people with obesity or overweight. Funding: Commercial Support - Eli Lilly and Company
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment with the GIP/GLP-1 receptor agonist, tirzepatide was associated with reduced albuminuria in patients with T2D or obesity, although most patients in these studies had normal albuminuria and did not have CKD.22,23”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [23]
In the citing paper
“Regarding co-agonist treatment, tirzepatide was recently shown in a post hoc analysis of the SURMOUNT-1 trial to also reduce UACR in overweight/obese people without T2D (88), and similar benefits for kidney function were shown in subjects with heart failure (89).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [88]
Citations
Cites
Still being checked.
Cited by
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
Self-citationHeerspink, H. J. L., Lu, Z., Du, Y., Duffin, K. L., Coskun, T., Haupt, A., & Hartman, M. L. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.03.049 · Cited by 23
Self-citationTirzepatide for adults living with obesity
Franco, J. V. A., Guo, Y., Varela, L. B., Aqra, Z., Alhalahla, M., Rodriguez, M. M., Salvador-Oscco, E., Araujo, B. P., Banda, S., Liquitay, C. M. E., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016018 · Cited by 22
Metadata
- Authors
- Heerspink, H. J., Friedman, A. N., Bjornstad, P., Raalte, D. H. V., Yang, Z., Stefanski, A., Chigutsa, F. B., Turfanda, I., Bunck, M., & de Oliveira, C. P.
- Affiliations
- University Medical Center Groningen (NL)
- Indiana University School of Medicine (US)
- University of Colorado Anschutz (US)
- Amsterdam University Medical Centers (NL)
- Eli Lilly (United States) (US)
- Eli Lilly and Company, Indianapolis, IN.
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2023-11
- Volume
- 34
- Issue
- 11S
- Pages
- 41-41
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W4397041251
- Cited by
- 3
- References
- 0
- Citations by year
- 2025: 3
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- tirzepatide, obesity, renal function, estimated glomerular filtration rate, cystatin C, albuminuria, chronic kidney disease, GIP/GLP-1 receptor agonist, weight loss, type 2 diabetes, cardiovascular risk, drug safety, overweight, blood pressure reduction, albumin-creatinine ratio
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Tirzepatide on Kidney Function in People with Excess Body Weight: A Post Hoc Analysis of the SURMOUNT-1 Trial: FR-OR47. https://app.cochat.ai/papers/10.1681/asn.20233411s141b
- The paper
- Heerspink, H. J., Friedman, A. N., Bjornstad, P., Raalte, D. H. V., Yang, Z., Stefanski, A., Chigutsa, F. B., Turfanda, I., Bunck, M., & de Oliveira, C. P. (2023). Effect of Tirzepatide on Kidney Function in People with Excess Body Weight: A Post Hoc Analysis of the SURMOUNT-1 Trial: FR-OR47. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.20233411s141b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.